Premium
COST‐EFFECTIVENESS AND COST‐UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED‐STAGE HODGKIN LYMPHOMA
Author(s) -
Prica A.,
Vijenthira A.,
Chan K.,
Cheung M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.106_2629
Subject(s) - medicine , abvd , incremental cost effectiveness ratio , quality adjusted life year , life expectancy , cost effectiveness , brentuximab vedotin , oncology , hodgkin lymphoma , lymphoma , population , risk analysis (engineering) , environmental health , chemotherapy , vincristine , cyclophosphamide